Tiziana Life Sciences Ltd
TLSADrugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Aug 7, 2026
3dMarket Overview
Stock performance and key metrics
3 upcoming, 0 past
TLSA Earnings Report
FQ end 2026-03
2 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
Foralumab Nasal
Multiple System Atrophy
Foralumab
Secondary Progressive Multiple Sclerosis
Foralumab TZLS-401 100 µg
Non-Active Secondary Progressive Multiple Sclerosis
Milciclib maleate
Hepatocellular Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Foralumab Nasal | Phase 2 | Multiple System Atrophy | - | - |
Foralumab | Phase 2 | Secondary Progressive Multiple Sclerosis | - | - |
Foralumab TZLS-401 100 µg | Phase 2 | Non-Active Secondary Progressive Multiple Sclerosis | - | - |
Milciclib maleate | Phase 2 | Hepatocellular Carcinoma | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Tiziana Life Sciences Ltd's drug pipeline?→
CatalystAlert tracks 4 drug candidates in Tiziana Life Sciences Ltd's (TLSA) pipeline across Phase 2. Its lead program is Foralumab Nasal (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Tiziana Life Sciences Ltd's next FDA catalyst?→
Tiziana Life Sciences Ltd's (TLSA) next tracked catalyst is a Earnings expected August 7, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TLSA biotech catalysts?→
Add TLSA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Tiziana Life Sciences Ltd's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.